Lördag 27 December | 05:19:04 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-10-22 07:50 Kvartalsrapport 2026-Q3
2026-07-17 07:50 Kvartalsrapport 2026-Q2
2026-04-29 N/A Årsstämma
2026-04-29 07:50 Kvartalsrapport 2026-Q1
2026-02-12 07:50 Bokslutskommuniké 2025
2025-10-22 - Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-06-11 - Extra Bolagsstämma 2025
2025-04-30 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2025-04-29 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-22 21:30:00

At an Extraordinary General Meeting of Vimian Group AB (publ) (“Vimian”) held on 11 June 2025, it was resolved to implement a long-term incentive program based on so-called hurdle shares and employee stock options (“LTIP 2025”). The Extraordinary General Meeting authorized the Board of Directors to resolve upon a new issue of class D shares, class E1 2025 shares, class E2 2025 shares, and class E3 2025 shares, and to repurchase the shares for further transfer to the participants in LTIP 2025. On 27 October 2025, the Board of Directors resolved on a new issue, repurchase and transfer of a number of shares under LTIP 2025. The Board of Directors has today, in light of additional participants and changes in participants’ category in the program, based on the authorizations granted by the Extraordinary General Meeting, resolved to carry out an additional new issue and subsequently repurchase a total of 596,437 shares, of which 418,269 class D shares, 59,390 class E1 2025 shares, 59,389 class E2 2025 shares and 59,389 E3 2025 shares.

As part of the implementation of LTIP 2025, 418,269 class D shares, 59,390 class E1 2025 shares, 59,389 class E2 2025 shares and 59,389 E3 2025 shares are issued to DNB Carnegie Investment Bank AB (“DNB Carnegie”) at a subscription price corresponding to the quota value per share (approximately SEK 0.001668). The share capital is thereby increased by approximately SEK 995. All issued shares will then, in accordance with the Board of Directors’ resolution, be repurchased by Vimian from DNB Carnegie at the same price for further transfer to the participants in LTIP 2025 in accordance with the terms and conditions resolved upon by the Extraordinary General Meeting.
 
The reasons for the deviation from shareholders’ preferential rights in the issue and the purpose of the repurchase are that the new issue and repurchase are part of the implementation of LTIP 2025. Class D shares, class E1 2025 shares, class E2 2025 shares, and class E3 2025 shares do not entitle the holder to dividends and entitle the holder to one-tenth (1/10) of a vote each in accordance with Vimian’s Articles of Association.